lipella.com Open in urlscan Pro
50.87.188.202  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content


LIPELLA PHARMACEUTICALS INC.

Empowering Cancer Survivorship

Menu
 * Home
 * Hemorrhagic Cystitis Clinical Trial
 * Radiation Cystitis Patient Registry
 * Management
 * Publications
 * Press Releases

Scroll down to content


ABOUT

Lipella is a privately-held biotechnology company with a focus on supportive
care to cancer survivors who acquire hemorrhagic cystitis, also called radiation
cystitis, when hemorrhagic cystitis occurs after pelvic radiation, as well as
improved surveillance and imaging of patients with a history of transitional
cell carcinoma. We are also applying our proprietary drug delivery to the oral
mucosa for the treatment of oral lichen planus.

Our lead product, LP-10 for hemorrhagic cystitis is currently in a phase-2,
multi-center clinical trial, and our pipeline asset, LP-310, recently received
FDA Type-B Pre-IND guidance. We maintain a pipeline of additional product
candidates consistent with our strategy of developing proprietary 505(b)(2)
assets that address highly-morbid indications where no adequate treatment(s)
exists.

Lipella maintains a sterile manufacturing facility in Pittsburgh, PA for the
production of clinical supplies and research products. Contact us at
info@lipella.com or 412-894-1853.

--------------------------------------------------------------------------------

We celebrate National Cancer Survivors Day!



Lipella Pharmaceuticals Inc.
7800 Susquehanna St, Suite 505
Pittsburgh, PA 15208
USA

1-412-894-1853
info@lipella.com

Lipella Pharmaceuticals Inc. Code of Ethics (link)

Proudly powered by WordPress